RT Journal Article
T1 Neurotoxicity prevention with a multimodal program (ATENTO) prior to cancer treatment versus throughout cancer treatment in women newly diagnosed for breast cancer: Protocol for a randomized clinical trial.
A1 Gonzalez-Santos, Angela
A1 Postigo-Martin, Paula
A1 Gallart-Aragon, Tania
A1 Esteban-Cornejo, Irene
A1 Lopez-Garzon, Maria
A1 Galiano-Castillo, Noelia
A1 Arroyo-Morales, Manuel
A1 Illescas-Montes, Rebeca
A1 Artacho-Cordon, Francisco
A1 Martin-Martin, Lydia
A1 Forneiro-Perez, Rocio
A1 Lozano-Lozano, Mario
A1 Fernandez-Lao, Carolina
A1 Ruiz-Vozmediano, Julia
A1 Sanchez-Salgado, Carmen
A1 Cantarero-Villanueva, Irene
K1 breast neoplasms
K1 neurotoxicity
K1 prehabilitation
K1 quality of life
K1 therapeutic exercise
AB A current challenge in breast cancer (BC) patients is how to reduce the side effects of cancer and cancer treatments and prevent a decrease in quality of life (QoL). Neurotoxic side effects, especially from chemotherapy, are present in up to 75% of women with BC, which implies a large impact on QoL. There is a special interest in the preventive possibilities of therapeutic exercise (TE) for these neurological sequelae, and the benefits of TE could be improved when it is combined with vagal activation techniques (VATs). This superiority randomized controlled trial aims to examine the feasibility and efficacy of an 8-week multimodal intervention (ATENTO) based on moderate-vigorous intensity and individualized TE (aerobic and strength exercises) and VAT (myofascial and breathing exercises), on neurotoxicity prevention in women with BC before starting adjuvant chemotherapy (ATENTO-B) versus throughout adjuvant chemotherapy (ATENTO-T). A sample of 56 women newly diagnosed with BC, as calculated with a power of 85%, will be randomly allocated into these two groups. This study could provide an impetus for the introduction of early multimodal intervention methods to prevent neurotoxicity and consequently avoid the QoL deterioration that BC patients presently suffer throughout their treatments.
PB John Wiley & Sons, Inc.
YR 2021
FD 2021-04-15
LK http://hdl.handle.net/10668/17760
UL http://hdl.handle.net/10668/17760
LA en
NO González-Santos Á, Postigo-Martin P, Gallart-Aragón T, Esteban-Cornejo I, Lopez-Garzon M, Galiano-Castillo N, et al. Neurotoxicity prevention with a multimodal program (ATENTO) prior to cancer treatment versus throughout cancer treatment in women newly diagnosed for breast cancer: Protocol for a randomized clinical trial. Res Nurs Health. 2021 Aug;44(4):598-607.
NO The authors thank the Asociación Española Contra el Cáncer (IDEAS19055CANT), the Spanish Ministry of Education Culture and Sport (MECD) (FPU17/00939, FPU18/03575), the Carlos III Health Institute (FI19/00230),​ and Carlos III Health Insitute and the European Regional Development Fund (FEDER) (PI18/01840), for funding this study and all participants of the study. IEC is supported by the Spanish Ministry of Economy and Competitiveness. This study was part of a Ph.D thesis conducted in the Clinical Medicine and Public Health Doctoral Studies of the University of Granada, Spain. Trial registration: ClinicalTrials. Gov identifier: NCT04583124.
DS RISalud
RD Apr 7, 2025